Extranodal marginal zone B-cell lymphoma of the ocular adnexa: evidence is insufficient to recommend chemotherapy, immunotherapy, or antibiotics as initial treatment for localized extranodal marginal zone B-cell lymphoma of the ocular adnexa

Background: Low-grade B-cell lymphomas located around the eye present unique challenges in diagnosis and treatment. Extranodal marginal zone B-cell lymphoma is the most common lymphoma of the ocular adnexa (conjunctiva, orbit, lacrimal gland, and eyelid). Methods: A systematic search of the relevant...

Full description

Saved in:
Bibliographic Details
Published in:Cancer control 2016-04, Vol.23 (2), p.140
Main Authors: Margo, Curtis E, Johnson, Jean Guffey, Setoodeh, Reza, Terpak, Lauren A
Format: Article
Language:English
Subjects:
Cancer
Care and treatment
Chemotherapy
Diagnosis
Evaluation
Lymphomas
Medical protocols
Methods
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Low-grade B-cell lymphomas located around the eye present unique challenges in diagnosis and treatment. Extranodal marginal zone B-cell lymphoma is the most common lymphoma of the ocular adnexa (conjunctiva, orbit, lacrimal gland, and eyelid). Methods: A systematic search of the relevant literature was performed. Material pertinent to the diagnosis, prognosis, pathogenesis, and treatment of extranodal marginal zone B-cell lymphoma of the ocular adnexa was identified, reviewed, and analyzed, focusing on management strategies for primary localized disease. Results: The primary cause of extranodal marginal zone B-cell lymphoma of the ocular adnexa remains elusive, although an infectious agent is suspected. Radiotherapy is the most common initial treatment for localized disease. Initial treatment with chemotherapy, immunotherapy, and antibiotics has shown promising results, but the number of series is limited and controlled trials do not exist. Conclusions: Although the long-term outcome of localized extranodal marginal zone B-cell lymphoma of the ocular adnexa is good, optimal treatment remains a goal. The variation in rates of local and systemic relapse among treated stage 1E tumors suggests that critical factors affecting outcomes are not fully understood. Radiotherapy is the standard of care; at this time, the evidence is insufficient to recommend chemotherapy, immunotherapy, or antibiotics for initial treatment of extranodal marginal zone B-cell lymphoma localized to the ocular adnexa. Well-controlled comparative studies are needed.
ISSN:1073-2748